

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/626,772	07/25/2003	Kazutomo Inoue	0020-5157P 1689		
2292	7590 02/22/2006		EXAMINER		
	EWART KOLASCH	CROUCH, DEBORAH			
PO BOX 747 FALLS CHU	/ JRCH, VA 22040-074	7	ART UNIT	PAPER NUMBER	
	•		1632		

DATE MAILED: 02/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No. Applicant(s)							
Office Action Summary		10/626,77	72	INOUE ET AL.					
		Examiner		Art Unit					
			Crouch, Ph.D.	1632					
Period fo	The MAILING DATE of this communication Reply	on appears on the	cover sheet with the c	orrespondence ad	ldress				
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD FOR FOR HEVER IS LONGER, FROM THE MAILIN isions of time may be available under the provisions of 37 C SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutory the toreply within the set or extended period for reply will, by the pely received by the Office later than three months after the period for reply will. See 37 CFR 1.704(b).	NG DATE OF TH CFR 1.136(a). In no evo- ion. period will apply and wi y statute, cause the app	IIS COMMUNICATION ent, however, may a reply be tim Il expire SIX (6) MONTHS from ication to become ABANDONE	J. nely filed the mailing date of this c D (35 U.S.C. § 133).	•				
Status									
1)	Responsive to communication(s) filed on								
	nis action is FINAL . 2b) This action is non-final.								
'=	secution as to the	e merits is							
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims								
4)⊠	4)⊠ Claim(s) <u>1-14</u> is/are pending in the application.								
=	4a) Of the above claim(s) is/are withdrawn from consideration.								
	5) Claim(s) is/are allowed.								
6)[6) Claim(s) is/are rejected.								
8)⊠	Claim(s) 1-14 are subject to restriction ar	nd/or election rec	uirement.						
Applicati	on Papers								
9)□	The specification is objected to by the Exa	aminer.							
10)	The drawing(s) filed on is/are: a)	accepted or b)	objected to by the E	Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
	Replacement drawing sheet(s) including the o	correction is require	ed if the drawing(s) is obj	ected to. See 37 Cl	FR 1.121(d).				
11)	The oath or declaration is objected to by t	he Examiner. No	te the attached Office	Action or form P7	ΓΟ-152.				
Priority u	nder 35 U.S.C. § 119								
_	Acknowledgment is made of a claim for fo	oreign priority und	der 35 U.S.C. § 119(a)	-(d) or (f).					
a)[a) All b) Some * c) None of:								
	1. Certified copies of the priority documents have been received.								
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the	-		d in this National	Stage				
* 0	application from the International B	*	` ''	_					
3	ee the attached detailed Office action for	a list of the certil	lea copies not receive	α.					
	42								
Attachment	•		4)	(DTO 442)					
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-94	1 8)	4) Interview Summary Paper No(s)/Mail Da						
3) 🔲 Infom	nation Disclosure Statement(s) (PTO-1449 or PTO/S No(s)/Mail Date	•	5) Notice of Informal P. 6) Other:		D-152)				

Art Unit: 1632

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 5, 6, 10, 12 and 13, drawn to a method of inducing differentiation of mammalian embryonic stem cells into functioning pancreatic cells, pancreatic cells, and methods of using the cells to treat disorders of pancreatic function classified in at least class 435, subclass 377.
- II. Claims 7, 8, 11 and 14 drawn to drawn to a method of inducing differentiation of mammalian embryonic stem cells into functioning nerve-like cells, pancreatic cells, and methods of using the cells to treat disorders in nerve function classified in at least class 435, subclass 377.

Claims 1-4 and 9 link(s) inventions I and II. The restriction requirement between the linked inventions is subject to the nonallowance of the linking claim(s), claims 1-4 and 9. Upon the allowance of the linking claim(s), the restriction requirement as to the linked inventions shall be withdrawn and any claim(s) depending from or otherwise including all the limitations of the allowable linking claim(s) will be entitled to examination in the instant application. Applicant(s) are advised that if any such claim(s) depending from or including all the limitations of the allowable linking claim(s) is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Inventions I and II are mutually exclusive and independent inventions. As evidenced by the claimed subject matter, the methods of differentiating pancreatic islet-like cells and nerve-like cells require materially different and separate media. Further, neither the

Art Unit: 1632

methods nor cells of invention I is needed to implement the methods or cells of invention II, or vice-versa.

Because these inventions are distinct for the reasons given above and have acquired because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper. Any search would not be co-extensive.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah Crouch, Ph.D. whose telephone number is 571-272-0727. The examiner can normally be reached on M-Fri, 7:30 AM to 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla, Ph.D. can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/626,772

Art Unit: 1632

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Deborah Crouch, Ph.D. Primary Examiner Art Unit 1632 Page 4

February 20, 2006